# ACTINIUM PHARMACEUTICALS, INC. (ATNM) · Edgar & Edgarette company card

> Actinium Pharmaceuticals (ATNM) grew revenue 11.1% in FY2025 to $0 million, operating margin -40274% against a -3.8% median for pharmaceutical preparations, equity 15.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1388320 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ATNM) · [JSON](https://www.pops4.com/boards/company/ATNM.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $90,000 |
| Revenue growth, 1 year | 11.1% |
| Revenue growth per year | — |
| Operating margin | -40274.4% (prior year -64098.8%) |
| Net margin | -37652.2% |
| Operating cash flow | −$25M |
| Capital spending | $104,000 |
| Free cash flow | −$25M |
| Cash | $48M |
| Long-term debt | — |
| Total assets | $52M |
| Total equity | $8M |
| Equity ÷ assets | 15.1% |
| Return on equity | -432.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -25.07 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$24.6M in FY2025); operating loss: a margin of -40274.4% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $90K (FY2025). Experience: revenue up 11.1% on the year; operating margin -40274.4%, up from -64098.8%. Soundness: equity 15.1% of assets, return on equity -432.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $51K and $91K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -40274.4% against a -3.8% median; growth 11.1% against 13.7%.

Range logged 2026-10-16, receipt e8c3102720af44b3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-08-14 ([filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/0001213900-26-090232-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-10-15 ([filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026109884/0001213900-26-109884-index.htm))

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026120788/0001213900-26-120788-index.htm)
- DEF 14A · filed 2026-10-15 · [filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026110022/0001213900-26-110022-index.htm)
- 8-K · filed 2026-10-15 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026109884/0001213900-26-109884-index.htm)
- 8-K · filed 2026-08-14 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/0001213900-26-090232-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026086769/0001213900-26-086769-index.htm)
- 8-K · filed 2026-06-18 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1388320/000121390026070193/0001213900-26-070193-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001388320.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1388320

## Cite

POPS4, Edgar & Edgarette: ACTINIUM PHARMACEUTICALS, INC. (ATNM) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ATNM. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

